Yi Luo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7222791/publications.pdf

Version: 2024-02-01

7	655	7	7
papers	citations	h-index	g-index
7	7	7	1080 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet, The, 2018, 392, 2705-2717.	6.3	374
2	Collagen biology and nonâ€invasive biomarkers of liver fibrosis. Liver International, 2020, 40, 736-750.	1.9	107
3	An Evaluation of the Collagen Fragments Related to Fibrogenesis and Fibrolysis in Nonalcoholic Steatohepatitis. Scientific Reports, 2018, 8, 12414.	1.6	53
4	Assessment of liver fibrosis progression and regression by a serological collagen turnover profile. American Journal of Physiology - Renal Physiology, 2019, 316, G25-G31.	1.6	42
5	SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH. Hepatology Communications, 2021, 5, 760-773.	2.0	38
6	Integrated plasma proteomics and lung transcriptomics reveal novel biomarkers in idiopathic pulmonary fibrosis. Respiratory Research, 2021, 22, 273.	1.4	21
7	LPA1 antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosis. Respiratory Research, 2022, 23, 61.	1.4	20